2019 ASCO Annual Meeting!
Session: Lung Cancer—Non-Small Cell Metastatic
Type: Poster Session
Time: Sunday June 2, 8:00 AM to 11:00 AM
Location: Hall A
Biomarker-directed precision oncology of pembrolizumab-based combination therapy for non-small cell lung cancer: Phase II KEYNOTE-495/KeyImPaCT study.
Metastatic Non-Small Cell Lung Cancer
Lung Cancer—Non-Small Cell Metastatic
2019 ASCO Annual Meeting
Poster Board Number:
Poster Session (Board #438b)
J Clin Oncol 37, 2019 (suppl; abstr TPS9117)
Author(s): Martin Gutierrez, Matthew David Hellmann, Matthew A. Gubens, Charu Aggarwal, Daniel Shao Weng Tan, Enriqueta Felip, Joanne Wing Yan Chiu, Jong Seok Lee, James Chih-Hsin Yang, Edward B. Garon, Andrea Basso, Hua Ma, Lawrence Fong, Alex Snyder, Jianda Yuan, Roy S. Herbst; Hackensack University Medical Center, Hackensack, NJ; Memorial Sloan Kettering Cancer Center, New York, NY; UCSF Medical Center, San Francisco, CA; University of Pennsylvania, Philadelphia, PA; SingHealth Duke NUS Academic Medical Centre, Singapore, Singapore; Vall d´Hebron University Hospital, Barcelona, Spain; University of Hong Kong, Hong Kong, China; Seoul National University Bundang Hospital, Seoul, South Korea; National Taiwan University, Taipei, Taiwan; University of California, Los Angeles, Los Angeles, CA; Merck & Co., Inc., Kenilworth, NJ; University of California San Francisco, San Francisco, CA; Yale University, New Haven, CT
Background: Pembrolizumab-based combination immunotherapy aims to improve clinical outcomes over pembrolizumab monotherapy. A biomarker-based therapeutic approach may be associated with improved response to different combination therapies of immune checkpoint inhibitors and may improve overall outcomes in NSCLC. The randomized, multicenter, open-label, phase 2 KEYNOTE-495 trial (